Company Overview and News

 
Atlas Cycles (Haryana) Limited - Financial Result Updates

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ATLASCYCLE 505029

 
Atlas Cycles (Haryana) Limited - Outcome of Board Meeting

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ATLASCYCLE 505029

 
Atlas Cycles (Haryana) Limited - Dividend Updates

2018-08-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ATLASCYCLE 505029

 
Atlas Cycles (Haryana) Limited - Outcome of Board Meeting

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ATLASCYCLE 505029

 
Atlas Cycles (Haryana) Limited - Financial Result Updates

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ATLASCYCLE 505029

3
Podcast | Digging deeper - Business of Family: The Munjals

2018-08-29 moneycontrol
Fill it, shut it, forget it, they said but the legacy that has the momentum and ambition to keep reinventing itself, remains perpetually relevant and memorable. And that is why when in 2015, the founder and chairman of Hero Cycles OP Munjal passed away, he left behind a brand that keeps growing younger and stronger and more diverse with each passing year.
BRK.A MAJESAUT 500267 ATLASCYCLE 505029

 
Atlas Cycles (Haryana) Limited - Outcome of Board Meeting

2018-06-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ATLASCYCLE 505029

 
Atlas Cycles (Haryana) Limited - Outcome of Board Meeting

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ATLASCYCLE 505029

3
Jet Air, Tata Motors, IFCI results on Wednesday

2018-05-22 thehindubusinessline
About 75 companies including Aries Agro, Atlas Cycles, Bajaj Electricals, CESC, Cosmo Films, Dhanlaxmi Bank, eClerx, Entertainment Network, Eros, Finolex, GE T&D, Godrej Industries, Grasim, GVK Power, HG Infra, IFCI, Indraprastha Gas, Jet Airways, Jain Irrigation, KPIT Tech, L&T Infotech, MEP Infra, Natco Pharma, Omaxe, Ramco Cements, Repco Home, Shipping Corp, SML Isuzu, Suntech Realty, Tata Motors and Vidhi Specialty will declare their quarter and full-year results on Wednesday.
GODREJIND PQRTY 524816 532617 532935 ATLASCYCLE 532514 IGL ARIES 508814 NATCOPHARM 505029 532180 500570 500031 TATAMOTORS RMCTY 505192 JETAIRWAYS PETRONET 532700 ENIL 532522 500260 SMLISUZU RAMCOCEM DHANBANK COSMOFILMS 500164 BAJAJELEC TTM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...